Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Change in Accured Expenses (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Change in Accured Expenses for 8 consecutive years, with $528000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 74.16% to $528000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.1 million, a 1104.69% decrease, with the full-year FY2024 number at -$2.1 million, down 193.92% from a year prior.
  • Change in Accured Expenses was $528000.0 for Q3 2025 at Precision Biosciences, down from $677000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.4 million in Q2 2022 to a low of -$5.8 million in Q1 2024.
  • A 5-year average of -$376736.8 and a median of $474000.0 in 2022 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 767.61% in 2022; the steepest drop was 139.98% in 2022.
  • Precision Biosciences' Change in Accured Expenses stood at $2.4 million in 2021, then tumbled by 82.45% to $421000.0 in 2022, then soared by 464.61% to $2.4 million in 2023, then plummeted by 106.56% to -$156000.0 in 2024, then surged by 438.46% to $528000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Change in Accured Expenses are $528000.0 (Q3 2025), $677000.0 (Q2 2025), and -$5.1 million (Q1 2025).